Wednesday, November 18, 2020

AFYX Therapeutics Sets Chief Medical Officer

San Diego-based biopharmaceuticals firm AFYX Therapeutics has named a new Chief Medical Officer, the company said this morning. The company appointed Dennis D. Kim, M.D., MBA to the position. Kim was most recently chief medical officer of Emerald Health Sciences (EHS) and later of its subsidiary Emerald Bioscience (EMBI), and also served at Zafgen, Inc., Orexigen Therapeutics, and EnteroMedics, Inc. AFYX Therapeutics is a biopharmacetuicals company focused on mucosal diseases; the company say it has compounds aimed at treatment of oral lichen planus and for the treatment of vulvar lichen sclerosus. More information »

---